HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sitamaquine overcomes ABC-mediated resistance to miltefosine and antimony in Leishmania.

Abstract
Although oral miltefosine represented an important therapeutic advance in the treatment of leishmaniasis, the appearance of resistance remains a serious threat. LMDR1/LABCB4, a P-glycoprotein-like transporter included in the Leishmania ABC (ATP-binding cassette) family, was the first molecule shown to be involved in experimental miltefosine resistance. LMDR1 pumps drugs out of the parasite, thereby decreasing their intracellular accumulation. Sitamaquine, another promising oral drug for leishmaniasis, is currently in phase 2b clinical trials. The physicochemical features of this drug suggested to us that it could be considered for use as an LMDR1 inhibitor. Indeed, we report herein that nonleishmanicidal concentrations of sitamaquine reverse miltefosine resistance in a multidrug resistance Leishmania tropica line that overexpresses LMDR1. This reversal effect is due to modulation of the LMDR1-mediated efflux of miltefosine. In addition, sitamaquine is not a substrate of LMDR1, as this transporter does not affect sitamaquine accumulation or sensitivity in the parasite. Likewise, we show that ketoconazole, another oral leishmanicidal drug known to interact with ABC transporters, is also able to reverse LMDR1-mediated miltefosine resistance, although with a lower efficiency than sitamaquine. Molecular docking on a three-dimensional homology model of LMDR1 showed different preferential binding sites for each substrate-inhibitor pair, thus explaining this different behavior. Finally, we show that sitamaquine is also able to modulate the antimony resistance mediated by MRPA/LABCC3, another ABC transporter involved in experimental and clinical antimony resistance in this parasite. Taken together, these data suggest that the combination of sitamaquine with miltefosine or antimony could avoid the appearance of resistance mediated by these membrane transporters in Leishmania.
AuthorsJosé M Pérez-Victoria, Boris I Bavchvarov, Iván R Torrecillas, Marta Martínez-García, Carmen López-Martín, Mercedes Campillo, Santiago Castanys, Francisco Gamarro
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 55 Issue 8 Pg. 3838-44 (Aug 2011) ISSN: 1098-6596 [Electronic] United States
PMID21646479 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • ATP-Binding Cassette Transporters
  • Aminoquinolines
  • Antiprotozoal Agents
  • Phosphorylcholine
  • miltefosine
  • Antimony
  • Ketoconazole
  • 8-aminoquinoline
Topics
  • ATP-Binding Cassette Transporters (antagonists & inhibitors, metabolism)
  • Aminoquinolines (metabolism, pharmacology, therapeutic use)
  • Antimony (pharmacology, therapeutic use)
  • Antiprotozoal Agents (metabolism, pharmacology)
  • Drug Resistance, Bacterial
  • Ketoconazole (metabolism, pharmacology)
  • Leishmania tropica (drug effects, metabolism)
  • Leishmaniasis (drug therapy)
  • Phosphorylcholine (analogs & derivatives, pharmacology, therapeutic use)
  • Protein Binding

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: